Establishment Labs (NASDAQ:ESTA) and Inogen (NASDAQ:INGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.
Institutional & Insider Ownership
21.8% of Establishment Labs shares are owned by institutional investors. Comparatively, 98.6% of Inogen shares are owned by institutional investors. 5.3% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent recommendations for Establishment Labs and Inogen, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Establishment Labs currently has a consensus price target of $36.67, suggesting a potential upside of 33.43%. Inogen has a consensus price target of $235.60, suggesting a potential upside of 66.67%. Given Inogen’s higher possible upside, analysts clearly believe Inogen is more favorable than Establishment Labs.
Valuation and Earnings
This table compares Establishment Labs and Inogen’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Establishment Labs||$34.68 million||16.28||-$34.90 million||N/A||N/A|
|Inogen||$249.44 million||12.10||$21.00 million||$1.31||107.91|
Inogen has higher revenue and earnings than Establishment Labs.
This table compares Establishment Labs and Inogen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Inogen beats Establishment Labs on 10 of the 11 factors compared between the two stocks.
Establishment Labs Company Profile
Establishment Labs Holdings Inc., a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue. The company sells its products through exclusive distributors and direct sales force in 60 countries worldwide. Establishment Labs Holdings Inc. was founded in 2004 and is headquartered in Alajuela, Costa Rica.
Inogen Company Profile
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.